Novel nucleic acid construct comprising poly(a) tail having secondary or tertiary structure and uses thereof

The introduction of complementary binding sequences at the poly(A) tail in mRNA constructs forms stable secondary structures, addressing degradation issues and enhancing protein expression, thus improving the efficacy of mRNA-based therapeutic agents.

WO2024248422A1PCT designated stage expired Publication Date: 2024-12-05SAMSUNG BIOLOGICS CO LTD

Patent Information

Application Number
PCT/KR2024/007048
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-26
Filing Date
2024-05-24
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current mRNA-based therapeutic agents face challenges in stability and protein expression levels due to degradation by exonucleases, with insufficient focus on optimizing the poly(A) tail, a critical region for mRNA stability.

Method used

Development of nucleic acid constructs with secondary or tertiary structures formed by complementary binding sequences at the poly(A) tail, specifically using stem-loop, bulged stem, or pseudoknot structures derived from virus sequences to enhance stability and protein expression without interfering with the coding sequence or untranslated regions.

Benefits of technology

The proposed nucleic acid constructs significantly increase intracellular stability and protein expression levels by forming protective secondary structures at the poly(A) tail, reducing degradation and enhancing translation efficiency, while maintaining universal applicability in vaccine and gene therapy contexts.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024007048_05122024_PF_FP_ABST
    Figure KR2024007048_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a novel nucleic acid construct having improved stability and protein expression level and uses thereof and, more specifically, to a nucleic acid construct comprising: a coding region encoding a polypeptide or protein; and a poly(A) tail having a secondary or tertiary structure, and a pharmaceutical composition for vaccine or gene therapy, comprising the nucleic acid construct. A nucleic acid construct platform according to the present invention exhibits more improved stability and protein expression rate in cells without interfering with CDS and UTR sequences and the like, and thus can be generally and effectively used in gene therapy, vaccine fields, and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Novel nucleic acid structure comprising a poly A tail having a secondary or tertiary structure and use thereof The present invention relates to a novel nucleic acid structure with improved stability and protein expression level and its use, and more particularly, to a nucleic acid structure comprising a coding region encoding a polypeptide or protein; and a poly(A) tail having a secondary or tertiary structure; and a vaccine or pharmaceutical composition for gene therapy comprising the nucleic acid structure. mRNA products produced using in vitro transcription (IVT) have recently attracted attention as a potential new drug class, either as vaccines or gene therapies. The concept behind using IVT mRNA as a drug is to deliver genetic messages into a patient's cells, ultimately aiming to prevent or alter specific disease states (Ugur Sahin, et al., Nat Rev Drug Discov. 2014 Oct;13(10):759-80). Unlike DNA, mRNA produced via IVT for therapeutic purposes is not transported to the nucleus but rather functions directly in the cytosol, eliminating concerns about genetic modification. Similarly to native mRNA, it can be engineered to transiently express proteins, reducing concerns about side effects. However, mRNA can be easily degraded by ribonuclease (RNase), which is commonly present both inside and outside cells. In vivo, mRNA degradation is critical to protein expression and, consequently, the efficacy of therapeutic mRNA preparations (Caroline C Friedel, et al., Nucleic Acids Res. 2009 Sep;37(17):e115). Therefore, various efforts have been made to avoid mRNA degradation and ultimately improve mRNA stability when producing therapeutic mRNAs. The degradation mechanism of single-strand mRNA generally proceeds by deadenylating the poly(A) sequence forming the 3'-terminal structure by deadenylase, and then exposing the 5'-terminal to exonuclease through a decapping mechanism (Nicole L Garneau, et al., Nat Rev Mol Cell Biol. 2007 Feb;8(2):113-26). To protect mRNA from these exonucleases, the 5'-terminus forms a cap structure and binds to a cap binding protein, and in the case of the 3'-terminus, poly(A) binding protein (PABP) binds to approximately 12 to 27 repeated adenosine sites to block the access of exonucleases (deadenylases), thereby increasing stability (Seung Hwan Lee, et al., Nucleic Acids Res. 2014 Feb;42(4):2697-707). Additionally, PABP plays an important role in improving protein translation efficiency by enabling mRNA to form a closed loop conformation through protein-protein interaction with translational initiation factors bound to the 5' Cap. The poly(A) region, commonly called the poly(A) tail, is a monotonous sequence region with repeating adenosine nucleotides. In the endogenous environment, 25 to 250 nt adenosine are generally synthesized and exist, but the number varies depending on the type of mRNA (Hyeshik Chang, et al., Mol Cell. 2014 Mar 20;53(6):1044-52). Currently, it is known that the number of poly(A) that can be synthesized in vitro is approximately 100, and it has been reported that when approximately 80 or more are randomly cleaved in E. coli during pDNA amplification (US 2017 / 0166905 A). Currently, attempts are continuously being made to increase mRNA stability and protein expression levels by stabilizing the poly(A) region. To date, efforts to enhance the stability and protein expression levels of therapeutic mRNA preparations in vivo have focused on optimization of the untranslated region (UTR) and coding sequence (CDS), nucleic acid variants (e.g., m1Ψ), and modification of the cap structure. Despite the poly(A) tail, located at the 3' end of the mRNA structure, playing a crucial role in mRNA stability mediated by exonucleases, related research remains limited. In relation to the development of mRNA vaccines, US 2021 / 0128716 A, EP 2831240 B, and US 2018 / 0185517 A suggest a form in which poly(C) and a histone stem-loop structure are inserted into the end of the mRNA poly(A) tail, and US 2017 / 0166905 A suggests a form in which an artificial linker-like base sequence is inserted in the middle of the mRNA poly(A) tail, and the linker allows 100 poly(A) bases to be consistently maintained during pDNA amplification and production in E. coli. US 2021 / 0128716 A and EP 2831240 B, respectively, demonstrated superiority in protein expression levels compared to the native form when mRNA was produced and delivered intracellularly. Therefore, these two reports confirm the importance of optimizing the poly A tail, and ongoing optimization of the poly A region is needed to increase stability and protein expression. Under these technical backgrounds, the present inventors have made great efforts to develop a platform that can increase the initial stability and protein expression rate of intracellular mRNA and maintain high efficiency consistency in any mRNA form without interference with UTR or CDS. As a result, the present inventors have confirmed that the platform can increase intracellular stability and protein expression level by forming a secondary structure or tertiary structure in the form of a stem-loop structure, a bulged stem structure, a pseudoknot structure, or a complete complementary binding structure using a safe complementary binding sequence derived from a virus or a gene at the middle and end of the poly(A) of an mRNA structure that can be used in the fields of gene therapy and vaccines, and completed the present invention. The above information described in this background section is solely intended to enhance understanding of the background of the present invention and may not include information that constitutes prior art already known to a person of ordinary skill in the art to which the present invention pertains. Summary of the invention The purpose of the present invention is to provide a novel nucleic acid structure having increased intracellular stability and protein expression level. Another object of the present invention is to provide a vaccine and vaccination comprising the nucleic acid structure. Another object of the present invention is to provide a pharmaceutical composition for gene therapy and a gene therapy method comprising the nucleic acid structure. Another object of the present invention is to provide the use of the nucleic acid construct for vaccine therapy and gene therapy, and the use of the nucleic acid construct for the manufacture of a vaccine or gene therapy medicament. To achieve the above object, the present invention provides a nucleic acid structure comprising a coding region (CDS) encoding a polypeptide or protein; and a poly(A) tail having a structure of any one of formulae (I) to (VIII). The present invention also provides a vaccine or a pharmaceutical composition for gene therapy comprising the nucleic acid structure. The present invention also provides a vaccination or gene therapy method comprising a step of administering the nucleic acid structure. The present invention also provides uses of the nucleic acid constructs for vaccine therapy and gene therapy. The present invention also provides the use of the nucleic acid construct for the manufacture of a vaccine or a medicament for gene therapy. Figure 1 is a schematic diagram of the DENV genome, with three complementary binding sites (5'-3' UAR / DAR / CS) indicated by boxes. Figure 2 is a schematic diagram of a poly(A) shielding structure utilizing CS (complementary binding sequence). Figure 3 is a schematic diagram of the secondary structure of the poly(A) shielding structure. Figure 4 is a schematic diagram of an mRNA expression cassette construct using DENV UAR / DAR / CS sequences. Figure 5 is a diagram showing that a secondary structure is formed through complementary binding using the SHAPE-Map assay, which enables structural prediction. Figure 6 is a diagram comparing protein expression rates depending on the presence or absence of a CS sequence. Figure 7 is a schematic diagram of an mRNA expression cassette structure according to various combinations of poly(A) numbers. Figure 8 is a graph showing the protein expression rates of the structures of Figure 7. Figure 9 is a schematic diagram of an mRNA expression cassette structure including various combinations, such as addition of poly(A) to the CS2 end (PLA309 to PLA311), a sequence combination designated as Mixed tail or Non-A (PLA312 to PLA320'), and a sequence combination designated as ARS (Adenine Rich Site) (PLA44, etc.). Figure 10 is a graph showing the protein expression efficiency of the structures of Figure 9. Figure 11 is a schematic diagram of an mRNA expression cassette structure containing an artificially produced CS sequence other than the DENV UAR / DAR / CS sequence and a graph showing the protein expression rate. Figure 12 is a diagram showing mRNA expression cassette constructs containing various structures and combinations, such as DENV CS, artificial sequences, and bulge sequences. Figure 13 is a graph showing the protein expression rates of the structures of Figure 12. Figure 14 is a schematic diagram of an mRNA expression cassette structure containing different CDSs. Figure 15 is a graph showing the protein expression rates of the structures of Figure 14. Figure 16 is a diagram showing an mRNA expression cassette structure containing different UTRs. Figure 17 is a graph showing the protein expression rates of the structures of Figure 16. Figure 18 is a drawing confirming the effect of increasing the stability of pDNA by the mRNA expression cassette structure according to the present invention. Figure 19 is a drawing confirming the inhibitory effect of dsRNA production by the mRNA expression cassette structure according to the present invention. Figure 20 is a drawing verifying immunogenicity by an mRNA expression cassette structure according to the present invention. Detailed description of the invention and preferred embodiments Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Generally, the nomenclature used herein is well known and commonly used in the art. In one embodiment of the present invention, a platform was developed that increases the stability and protein expression rate of intracellular mRNA by forming a secondary structure or tertiary structure in the form of a stem loop structure, a bulged stem structure, a pseudoknot structure, or a complete complementary binding structure using a complementary binding sequence inside and outside the poly(A) of an mRNA structure, and can always maintain consistently high efficiency in any mRNA sequence without interference with a UTR or CDS sequence. Accordingly, the present invention relates, in one aspect, to a nucleic acid structure comprising a coding region (CDS) encoding a polypeptide or protein; and a poly(A) tail having a structure of any one of the following formulae (I) to (VIII). In the present invention, the G / C / U refers to G (guanine), C (cytosine), or U (uracil). The structure containing the G / C / U includes a sequence combination called Mixed tail or Non-A, which has a functionally similar action to poly(A). The above N refers to a sequence in which U (uracil), G (guanine), A (adenine), or C (cytosine) are combined, and may be a random base that maintains the structure and function of the poly (A) tail. In one embodiment of the present invention, the N may be characterized as a sequence named ARS (Adenine Rich Site) having a function similar to poly (A). The above A may be a random base that maintains the structure and function of the adenine or poly(A) tail. In the above chemical formulas (I) to (VIII), m may be an integer from 5 to 200, and n may be an integer from 3 to 200, but is not limited thereto. In the present invention, it may be characterized in that at least one of m or n is an integer of 20 or less, but is not limited thereto. In the present invention, m may be an integer from 10 to 200, preferably an integer from 10 to 150, more preferably an integer from 20 to 100, and most preferably an integer from 30 to 80, but is not limited thereto. In the present invention, n may be an integer of 3 to 200, preferably an integer of 5 to 100, more preferably an integer of 8 to 80, and most preferably an integer of 10 to 50, but is not limited thereto. In the above chemical formulas (I) to (VIII), o may be characterized as being an integer of 3 to 200, but is not limited thereto. Preferably, it may be characterized as being an integer of 12 to 150, more preferably 20 to 100, and most preferably 30 to 70, but is not limited thereto. In the above chemical formulas (I) to (VIII), p may be an integer from 1 to 10, q may be an integer from 0 to 200, r and s may be integers from 1 to 30, x and x' may be integers from 1 to 10, and y and y' may be integers from 0 to 80, but are not limited thereto. In the present invention, the poly A tail may be characterized by having a structure of the chemical formula (I), wherein m is an integer from 30 to 80, n is an integer from 12 to 50, o is an integer from 12 to 60, and p is an integer from 1 to 5, but is not limited thereto. In the above chemical formulas (I) to (VIII), CS1 and CS2 may be characterized by complementary binding to each other, and may be applied without limitation as long as it is a sequence that increases the stability of the nucleic acid structure and the protein expression rate without interfering with the UTR or CDS sequence. The above CS1 and CS2 may be characterized by each independently consisting of 5 to 100 nucleotides, preferably 10 to 80, more preferably 20 to 60, and most preferably 30 to 50 nucleotides, but are not limited thereto. In the present invention, the CS1 and CS2 may be characterized by being complementarily combined with each other to form a stem-loop structure, a bulged stem structure, or a pseudoknot structure, or being complementarily combined by 30% to 100%. The above CS1 and CS2 may be characterized by being complementarily combined at 30% to 100%, 40% to 100%, 50% to 100%, 60% to 100%, 70% to 100%, 80% to 100%, 90% to 100%, 95% to 100%, 96% to 100%, 97% to 100%, 98% to 100%, 99% to 100% or 100%, but are not limited thereto. In the present invention, the CS1 may be characterized by being represented by any one of the base sequences of SEQ ID NO: 1 to SEQ ID NO: 9, and the CS2 may be characterized by being represented by any one of the base sequences of SEQ ID NO: 10 to SEQ ID NO: 18, but is not limited thereto. CS1: Sequence number 1: 5'-AGAGAGCAGACUCUGUUGAAAUACCAACGUCAAUAUGCUG-3' Sequence number 2: 5'-GAGAGCAGAUCUCUGUUGAAAUACCAACGUCAAUAUGCUG-3' Sequence number 3: 5'-AUCCGGUUGCGUUGUGAAUCGCGCCACUCCUAACUUGGACC-3' Sequence number 4: 5'-UCCGGUUGCGUUGUGAAUCGCGCCCACACCUAACUUGGACC-3' Sequence number 5: 5'-UCCGGUUGCGUUGUGGUUGAAUAACCAACCUAACUUGGACC-3' Sequence number 6: 5'-CCGUCGAUUGUCCCACGUUGAAUAACCAACCGGACCGCUAGCC-3' Sequence number 7: 5'-AGAGCAGAUGUUGAAUAACCAACGUCUG-3' Sequence number 8: 5'-AGAGAGCAGAUCGAUACAACGUCAAUGCUG-3' Sequence number 9: 5'-AGAGAGCAGAUCCUCUGUCAAUAUGCUG-3' CS2: Sequence number 10: 5'-CAGCAUAUUGACGCUGGGAAAGACCAGAGAUCUGCUCUCU-3' Sequence number 11: 5'-GGUCCAAGUUAGGAAAGUAUCAACUCGCAACGCAACCGGA-3' Sequence number 12: 5'-CAGCAUAUUGACUUGGUUAUUCAACAGAGAUCUGCUCUCU-3' Sequence number 13: 5'-GGUCCAAGUUAGGCGUGUAUCAACUCGCAACGCAACCGGA-3' Sequence number 14: 5'-GGUCCAAGUUAGGCUGGGAAAGACCCGCAACGCAACCGGA-3' Sequence number 15: 5'-GGCUAGCGUCCGGCUGGGAAAGACCGUGGACAAUCGACGG-3' Sequence number 16: 5'-CAGACCGGGGAAAGACCAUCUGCUCU-3' Sequence number 17: 5'-CAGCAUUGACGCUGGAGAGAUCUGCUCUCU-3' Sequence number 18: 5'-CAGCAUAUUGACAGAGAUCUGCUCUCU-3' Preferably, the CS1 and CS2 may be sequences that do not cause a pathogenic effect derived from an RNA virus, and more preferably, the CS1 and CS2 may be characterized by being conserved sequences derived from a dengue virus (DENV), but are not limited thereto. In the present invention, the poly A tail may be characterized by being represented by any one of the base sequences of SEQ ID NO: 24 and SEQ ID NO: 29 to SEQ ID NO: 102, but is not limited thereto. As used herein, the term "nucleic acid" preferably refers to DNA or RNA. In the present invention, "nucleic acid structure" may be used to mean a DNA structure, an RNA structure, an mRNA structure, etc., and may preferably be an mRNA structure, but is not limited thereto. In relation to the above nucleic acids, the terms "polynucleotide," "nucleotide," "nucleotide sequence," and "oligonucleotide" are used interchangeably. Polynucleotides of any length, deoxyribonucleotides or ribonucleotides, or analogs thereof, may be included. Polynucleotides may have any three-dimensional structure and may perform any function, known or unknown. Polynucleotides may include one or more modified nucleotides, such as methylated nucleotides and nucleotide analogs. Modifications to the nucleotide structure may occur before or after assembly of the polymer. Preferably, the nucleic acid is a polymer comprising or consisting of nucleotide monomers covalently linked to each other by phosphodiester bonds of a sugar / phosphate backbone. "Nucleic acid" may include modified nucleic acids, such as base-modified, sugar-modified, or backbone-modified DNA or RNA molecules. In the present invention, the nucleic acid may be characterized as comprising an unmodified or modified nucleic acid. The modified nucleic acid may be characterized as being selected from the group consisting of pseudouridine (Ψ), N1-methyl-pseudouridine (m1Ψ), 5-methyl-uridine (5-methyluridine, m5U), 2-thio-uridine (2-thiouridine, s2U), 2'-O-methyl-uridine (2'-O-methyl-U, Um), 5-methyl-cytidine (5-methylcytidine, m5C), and 5-methoxy-uridine (5-methoxyuridine, 5moU), but is not limited thereto. In this specification, the term "DNA" is an abbreviation for deoxyribonucleic acid. This is a polymer made of nucleic acid molecules, i.e., nucleotides. These nucleotides are usually deoxyadenosine monophosphate, deoxythymidine monophosphate, deoxyguanosine monophosphate, and deoxycytidine monophosphate monomers, and are composed of a sugar (deoxyribose), a base, and a phosphate, and are polymerized by a unique backbone structure. The backbone structure is typically formed by the sugar moiety of the first nucleotide, i.e., deoxyribose, and the phosphate moiety of the second nucleotide, and the phosphodiester bond between adjacent monomers. The specific order of the monomers, i.e., the order of the bases linked to the sugar / phosphate backbone, is called the DNA sequence. DNA can be single-stranded or double-stranded. In double-stranded form, nucleotides of the first strand typically hybridize with nucleotides of the second strand, for example, by A / T base pairing and G / C base pairing. As used herein, the term "RNA" stands for ribonucleic acid, a nucleic acid molecule, i.e., a polymer composed of nucleotides. Examples include messenger RNA (mRNA). Nucleotides are typically adenosine monophosphate, uridine monophosphate, guanosine monophosphate, and cytidine monophosphate monomers linked together via a so-called backbone. The backbone is formed first by a sugar, such as ribose, and second by phosphodiester bonds between adjacent monomers, the phosphate moieties. The specific sequence of monomers is called an RNA sequence. Messenger RNA typically provides a nucleotide sequence that can be translated into the amino acid sequence of a specific peptide or protein. Typically, mRNA comprises a 5'-cap, a 5'-UTR, an open reading frame (ORF) (or CDS), a 3'-UTR, and a poly(A) sequence. Aside from messenger RNA, several noncoding forms of RNA exist that can be involved in the regulation of transcription and / or translation. In the present invention, the nucleic acid structure may be characterized by further including a 5'-untranslated region (5'-UTR) and a 3'-untranslated region (3'-UTR) connected to both ends of the coding region; and a 5'-cap or IRES connected to the 5'-untranslated region, but is not limited thereto. Preferably, the nucleic acid structure may be characterized by having a structure represented by the following chemical formula (IX) or chemical formula (X), but is not limited thereto. Chemical Formula (IX): 5'-cap - 5'-UTR - CDS - 3'-UTR - [Chemical Formula (I) to (VIII)] Chemical Formula (X): 5' - IRES - 5'-UTR - CDS - 3'-UTR - [Chemical Formula (I) to (VIII)] In the present invention, the term “5'-untranslated region (5'-UTR)” refers to a nucleic acid molecule located 5' (i.e., "upstream") of a coding region and not translated into a protein. Typically, the 5'-UTR begins at the transcription start site and ends one nucleotide before the start codon of the coding region. Preferably, the 5'-UTR is 20, 30, 40, or 50 or more nucleotides in length. The 5'-UTR may contain elements for regulating gene expression, so-called regulatory elements. Such regulatory elements may be, for example, ribosome binding sites. The 5'-UTR may be post-transcriptionally modified, for example, by the addition of a 5'-cap. The 5'-UTR of an mRNA is not translated into an amino acid sequence. The 5'-UTR sequence is typically encoded by a gene, which is transcribed into each mRNA during gene expression. The genomic sequence is first transcribed into a premature mRNA containing an optional intron. The premature mRNA is further processed into a mature mRNA during a maturation process. This maturation process includes modifications of the 3'-end, such as 5'-capping, splicing of the premature mRNA to truncate the premature mRNA into optional introns, and polyadenylation of the 3'-end of the premature mRNA. In the present invention, the 5'-UTR corresponds to the sequence of the mature mRNA located between the start codon and, for example, the 5'-cap. Preferably, the 5'-UTR corresponds to a sequence extending from a nucleotide located 3' to the 5'-cap, more preferably a nucleotide immediately 3' to the 5'-cap, to a nucleotide located 5' to the start codon of the protein coding region, preferably a nucleotide immediately 5' to the start codon of the protein coding region. The nucleotide immediately 3' to the 5'-cap of the mature mRNA typically corresponds to the transcription start site.The term "corresponding" means that the 5'-UTR sequence may be an RNA sequence, such as the mRNA sequence used to define the 5'-UTR sequence, or a DNA sequence corresponding to such an RNA sequence. In the present invention, the term “3'-untranslated region (3'-UTR)” refers to a portion of an artificial nucleic acid molecule that is located 3' (i.e., "downstream") of a coding region and is not translated into a protein. Typically, the 3'-UTR is a region of an mRNA located between the protein coding region (ORF or CDS) and the poly(A) sequence of the mRNA. In the present invention, the term 3'-UTR may include elements that are not encoded as a template for RNA transcription. The 3'-UTR sequence is usually encoded by a gene that is transcribed into mRNA during the gene expression process. In the present invention, the 3'-UTR corresponds to a sequence of a mature mRNA located between the stop codons of the protein coding region, preferably immediately 3' to the stop codon of the protein coding region. The term “corresponds” means that the 3'-UTR sequence may be an RNA sequence, such as the mRNA sequence used to define the 3'-UTR sequence, or a DNA sequence corresponding to such an RNA sequence. Preferably, the 3'-UTR is at least 20, 30, 40 or 50 nucleotides in length. In the present invention, the term “5’-cap” refers to an independent component that “caps” the 5’-terminus located at the 5’ start site of mRNA. Generally, the cap structure serves to initiate protein synthesis and protect mRNA from the action of nucleases. The 5’-cap can typically be formed by a modified nucleotide, particularly a derivative of a guanine nucleotide. Preferably, the 5’-cap is linked to the 5’-terminus via a 5’-5’-triphosphate linkage. The 5’-cap is in a methylated form, for example, m7GpppN, where N is the terminal 5’ nucleotide of the nucleic acid to which the 5’-cap is linked, typically the 5’-terminus of RNA. Additional examples of 5'-cap structures include glyceryl, inverted deoxy abasic residue (some), 4',5' methylene nucleotides, 1-(beta-D-erythrofuranosyl) nucleotides, 4'-thio nucleotides, carbocyclic nucleotides, 1,5-anhydrohexitol nucleotides, L-nucleotides, alpha-nucleotides, modified base nucleotides, threo-pentofuranosyl nucleotides, acyclic 3',4'-seconucleotides, acyclic 3,4-dihydroxybutyl nucleotides, acyclic 3,5 dihydroxypentyl nucleotides, some 3'-3'-inverted nucleotides, some 3'-3'-inverted abasic residues, some 3'-2'-inverted nucleotides, and 3'-2'-inverted Some of the non-base moieties include 1,4-butanediol phosphate, 3'-phosphoramidate, hexyl phosphate, aminohexyl phosphate, 3'-phosphate, 3' phosphorothioate, phosphorodithioate, or bridging or non-bridging methylphosphonate moieties. The term "IRES (Internal Ribosome Entry Site)" in the present invention is known to be an internal ribosome entry point or ribosome binding site that forms a loop structure on mRNA and induces translation initiation through a mechanism independent of the cap. By utilizing this, when an IRES is positioned between two or more genes and produced as a single vector, two genes can be simultaneously expressed on a single mRNA. Accordingly, inserting an IRES region to induce expression of a target gene is widely used in genetic recombination technology. In the present invention, “CDS (coding sequence)” means a coding region encoding a target polypeptide or protein, and is used interchangeably with ORF (open reading frame) in the present specification. The polypeptide or protein may be, but is not limited to, (a) a therapeutically active protein or peptide; or (b) an antigen selected from the group consisting of tumor antigens, pathogenic antigens, viral antigens, protozoal antigens, bacterial antigens, allergenic antigens, and autoimmune antigens. Depending on the gene to be inserted into the coding region, the nucleic acid construct according to the present invention can be used for gene vaccine therapy or gene therapy for autoimmune diseases, infectious diseases, cancer or tumor-related diseases, inflammatory diseases, etc. Specifically, when the nucleic acid structure according to the present invention is used as a vaccine for vaccine therapy, the CDS may be a region encoding all or part of a region of a viral antigen that can cause infection in humans and animals, such as influenza virus, coronavirus, varicella zoster virus, human papillomavirus, Zika virus, herpes virus, AIDS virus, SFTS virus, measles virus, Ebola virus, MERS virus, hepatitis virus, avian influenza, rabies virus, foot-and-mouth disease virus, respiratory syncytial virus, etc., but is not limited thereto. In addition, when the nucleic acid structure of the present invention is used as a concept of a gene therapy agent by expressing a protein or antigen, the CDS may be a region encoding all or part of the sequence of a protein drug, antibody, disease-related antigen, etc., but is not limited thereto. The above disease-related antigens include 4-1BB, integrin, amyloid beta, angiopoietin (angiopoietin 1 or 2), angiopoietin-like substance 3, B-cell activating factor (BAFF), BAFF-R, BCMA, B7-H3, complement 5, CCR4, CD3, CD4, CD6, CD11a, CD19, CD20, CD22, CD30, CD33, CD38, CD52, CD62, CD79b, CD80, CGRP, Claudin-18, complement factor D, CTLA4, DLL3, EGF receptor, hemophilia factor, FGF23, folate receptor, GD2, GM-CSF, HER2, HER3, interferon receptor, interferon gamma, It may be selected from the group consisting of IgE, IGF-1 receptor, interleukin-1, interleukin-2, interleukin-2 receptor, interleukin-4, interleukin-4 receptor, interleukin-5, interleukin-5 receptor, interleukin-6, interleukin-6 receptor, interleukin-7, interleukin-12 / 23, interleukin-13, interleukin-17A, interleukin-17 receptor A, interleukin-31 receptor, interleukin-36 receptor, TGF-beta, TGF-beta receptor, LAG3, LFA3, NGF, PVSK9, PD-1, PD-L1, TIGIT, TIM3, GITR, KLRG1, OX40, OX40L, RANK-L, SLAMF7, tissue factor, TNF, VEGF and VEGF receptor, but is not limited thereto. The above antibody may be used without limitation as long as it is an antibody used for treating a disease-related condition, preferably a therapeutic antibody against the disease-related antigen, and more preferably an antibody drug currently on the market or in the clinical trial stage, but is not limited thereto. In addition, the protein pharmaceutical is a drug composed of amino acids and exhibits a disease treatment or prevention effect through the activity of the protein, and refers to a drug composed of proteins, including antibody pharmaceuticals, and may be selected from the group consisting of cytokines, therapeutic enzymes, hormones, soluble receptors and fusion proteins thereof, insulin or analogues thereof, BMP (Bone Morphogenetic Protein), EPO (erythropoietin), and serum derived proteins, but is not limited thereto. As a specific example, the cytokine may be selected from the group consisting of interferon, interleukin, colony stimulating factor (CSF), tumor necrosis factor (TNF), and tissue growth factor (TGF), but is not limited thereto, and the therapeutic enzyme may be selected from the group consisting of beta-glucocerebrosidase and agalsidase beta, but is not limited thereto. In addition, the soluble receptor refers to the extracellular domain of the receptor, and its fusion protein refers to a protein in which the soluble receptor is fused with the Fc region of an antibody, etc., and includes a form in which the Fc region is fused to the TNF-α soluble receptor (e.g., a product with the generic name Etanercept), a form in which the Fc region is fused to the VEGF soluble receptor (e.g., a product with the generic name Aflibercept and similar forms), a form in which the Fc region is fused to CTLA-4 (e.g., a product with the generic name Abatacept or Belatacept and similar forms), a form in which the Fc region is fused to the interleukin-1 soluble receptor (e.g., a product with the generic name Rilonacept and similar forms), a form in which the Fc region is fused to the LFA3 soluble receptor (e.g., a product with the generic name Alefacept and similar forms), etc. Examples may include, but are not limited to: The above hormone refers to a hormone or an analogue thereof injected externally to treat or prevent diseases caused by hormone deficiency, etc., and examples thereof include, but are not limited to, human growth hormone, estrogen, and progesterone, and the above plasma-derived protein refers to a protein present in plasma, and refers to both those extracted from plasma and those produced recombinantly, and examples thereof include, but are not limited to, fibrinogen, von Willebrand Factor, albumin, thrombin, FII (Factor II), FV (Factor V), FVII (Factor VII), FVIII (Factor VIII), FIX (Factor IX), FX (Factor X), and FXI (Factor XI). In the present invention, a template DNA (e.g., plasmid DNA (pDNA)) can be prepared to produce a nucleic acid structure containing mRNA of a gene encoding a target polypeptide or protein by an in-vitro transcription (IVT) method. mRNA produced by the IVT method can be purified by a purification method known in the art, and the purification method may include, but is not limited to, multimodal chromatography, RP-HPLC (Reversed-phase high-performance liquid chromatography), SEC (Size-exclusion HPLC), IEC (Ion exchange HPLC), cellulose chromatography, Oligo-dT (oligo-deoxythymidine acid), or TFF (Tangential flow filtration). In the present invention, the plasmid DNA for expressing the nucleic acid construct using the IVT method may additionally include a promoter sequence. The promoter may be located upstream of the 5'-UTR. The promoter may include elements necessary for transcription, such as an RNA polymerase promoter. It may include a phage RNA polymerase promoter such as T7, SP6, or T3, preferably a T7 or SP6 promoter encoding an mRNA sequence. In another aspect, the present invention relates to a vaccine or a pharmaceutical composition for gene therapy comprising the nucleic acid structure. In another aspect, the present invention relates to a vaccine therapy or gene therapy method comprising a step of administering the nucleic acid structure to a subject in need of treatment or prevention. In another aspect, the present invention relates to the use of the nucleic acid construct for vaccine therapy and gene therapy. In another aspect, the present invention relates to the use of the nucleic acid construct for the manufacture of a vaccine or a medicament for gene therapy. The term "vaccine" in the present invention is understood to refer to a prophylactic or therapeutic substance that provides at least one antigen, preferably an immunogen. The antigen or immunogen may be derived from any material suitable for vaccination. For example, the antigen or immunogen may be derived from a pathogen, such as a bacterial or viral particle, or from a tumor or cancerous tissue. The antigen or immunogen stimulates the body's adaptive immune system, which provides an adaptive immune response. The term "prevention" in the present invention refers to any action that prevents the onset of a disease or delays its progression through the administration of the composition. Furthermore, the term "treatment" as used herein refers to any action that improves, alleviates, or completely cures the symptoms of a disease through the administration of the composition. The term “gene therapy agent” of the present invention may be an anticancer agent, an immunotherapy agent, a CAR-T agent, or a treatment agent using CRISPR and its derivatives, but is not limited thereto, and the description of a case where the nucleic acid structure of the present invention is used as a concept of a gene therapy agent may be applied. In the present invention, the pharmaceutical composition may include a delivery means for delivering mRNA. The nucleic acid structure according to the present invention can be delivered via liposomes, LNPs (lipid nano-particles) or various nanoparticles. Liposomes or LNPs contain cationic lipids, non-cationic lipids, or neutral lipids, and may additionally contain other lipids such as polyethylene glycol (PEG) or cholesterol. Such mRNA delivery vehicles are specifically described in US 2018 / 0311176 A, US 2019 / 0032051 A, US 2021 / 0046192 A, WO 2018 / 081480 A, WO 2020 / 097540 A, WO 2020 / 097548 A, WO 2021 / 007278 A, etc., which are incorporated herein by reference. 상기 양이온성 지질은 US 2018 / 0311176 A, US 2019 / 0032051 A 등을 통해 구체적으로 예시되어 있으며, 예를 들어 N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(I-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), N-(I-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-dimethyl-2,3-dioleyloxy)propylamine (DODMA), 1,2-DiLinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1,2-Dilinoleylcarbamoyloxy-3-dimethylaminopropane (DLin-C-DAP), 1,2-Dilinoleyoxy-3-(dimethylamino)acetoxypropane (DLin-DAC), 1,2-Dilinoleyoxy-3-morpholinopropane (DLin-MA), 1,2-Dilinoleoyl-3-dimethylaminopropane (DLinDAP), 1,2-Dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), 1-Linoleoyl-2-linoleyloxy-3-dimethylaminopropane (DLin-2-DMAP), 1,2-Dilinoleyloxy-3-trimethylaminopropane chloride salt (DLin-TMA.Cl), 1,2-Dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.Cl), 1,2-Dilinoleyloxy-3-(N-methylpiperazino)propane (DLin-MPZ), 3-(N,N-Dilinoleylamino)-1,2-propanediol (DLinAP), 3-(N,N-Dioleylamino)-1,2-propanedio (DOAP), 1,2-Dilinoleyloxo-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), 1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA), 2,2-Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA) 또는 이들의 유사체, (3aR,5s,6aS)-N,N-dimethyl-2,2-di((9Z,12Z)-octadeca-9, 12-dienyl)tetrahydro-3aH-cyclopenta[d][1,3]dioxol-5-amine (ALN100), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (MC3), 1, 1′-(2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethylazanediyl)didodecan-2-ol (Tech G1), 2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane, β-L-arginyl-2, 3-L-diaminopropionic acid-N-palmityl-N-oleylamide trihydrochloride, N′,N′-dioctadecyl-N-4, 8-diaza-10-aminodecanoylglycine amide.

[0071] , 1,2-dilinoleyloxy-3-dimethylaminopropane, DLin-KC2-DMA, amino lipid 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA, 1), 1,2-distearloxy- / V,N-dimethylaminopropane (DSDMA), dilinoleylmethyl-4-dimethylaminobutyrate (DLin-MC3-DMA), DLin-D-DMA, C12-200, 98N12-5, (20Z,23Z)-N,N-dimethylnonacosa-20,23-dien-10-amine, (17Z,20Z)-N,N-dimemylhexacosa-17,20-dien-9-amine, (1Z,19Z)-N5N-dimethylpentacosa-16,19-dien-8-amine, (13Z,16Z)-N,N-dimethyldocosa-13,16-dien-5-amine, (12Z,15Z)-N,N-dimethylhenicosa-12,15-dien-4-amine, (14Z,17Z)-N,N-dimethyltricosa-14,17-dien-6-amine, (15Z,18Z)-N,N-dimethyltetracosa-15,18-dien-7-amine, (18Z,21Z)-N,N-dimethylheptacosa-18,21-dien-10-amine, (15Z,18Z)-N,N-dimethyltetracosa-15,18-dien-5-amine, (14Z,17Z)-N,N-dimethyltricosa-14,17-dien-4-amine, (19Z,22Z)-N,N-dimethyloctacosa-19,22-dien-9-amine, (18Z,21Z)-N,N-dimethylheptacosa-18,21-dien-8-amine, (17Z,20Z)-N,N-dimethylhexacosa-17,20-dien-7-amine, (16Z,19Z)-N,N-dimethylpentacosa-16,19-dien-6-amine, (22Z,25Z)-N,N-dimethylhentriaconta-22,25-dien-10-amine, (21Z,24Z)-N,N-dimethyltriaconta-21,24-dien-9-amine, (18Z)-N,N-dimethylheptacos-18-en-10-amine, (17Z)-N,N-dimethylhexacos-17-en-9-amine, (19Z,22Z)-N,N-dimethyloctacosa-19,22-dien-7-amine, N,N-dimethylheptacosan-10-amine, (20Z,23Z)-N-ethyl-N-methylnonacosa-20,23-dien-10-amine, 1-[(11Z,14Z)-1-nonylicosa-11,14-dien-1-yl]pyrrolidine, (20Z)-N,N-dimethylheptacos-20-en-10-amine, (15Z)-N,N-dimethyleptacos-15-en-10-amine, (14Z)-N,N-dimethylnonacos-14-en-10-amine, (17Z)-N,N-dimethylnonacos-17-en-10-amine, (24Z)-N,N-dimethyltritriacont-24-en-10-amine, (20Z)-N,N-dimethylnonacos-20-en-10-amine, (22Z)-N,N-dimethylhentriacont-22-en-10-amine, (16Z)-N,N-dimethylpentacos-16-en-8-amine, (12Z,15Z)-N,N-dimethyl-2-nonylhenicosa-12,15-dien-1-amine, (13Z,16Z)-N,N-dimethyl-3-nonyldocosa-13,16-dien-1-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]eptadecan-8-amine, 1-[(1S,2R)-2-hexylcyclopropyl]-N,N-dimethylnonadecan-10-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]nonadecan-10-amine, N,N-dimethyl-21-[(1S,2R)-2-octylcyclopropyl]henicosan-10-amine,N,N-dimeth-yl-1-[(1S,2S)-2-{[(1R,2R)-2-pentylcyclopropyl]methyl}cyclopropyl]nonadecan-10-amine,N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]hexadecan-8-amine, N,N-dimethyl-[(1R,2S)-2-undecylcyclopropyl]tetradecan-5-amine, N,N-dimethyl-3-{7-[(1 S,2R)-2-octylcyclopropyl]heptyl}dodecan-1-amine, 1-[(1R,2S)-2-heptylcyclopropyl]-N,N-dimethyloctadecan-9-amine, 1-[(1S,2R)-2-decylcyclopropyl]-N,N-dimethylpentadecan-6-amine, N,N-dimethyl-1-[(1S,2R)-2-octylcyclopropyl]pentadecan-8-amine, R-N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octyloxy)propa-n-2-amine, S-N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-(octy-loxy)propan-2-amine, 1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-Roctyloxy)methyl]ethyl}pyrro-lidine, (2S)-N,N-dimethyl-1-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-3-[(5Z)-oct-5-en-1-yloxy]propan-2-amine, 1-{2-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]-1-[(octyloxy)methyl]ethyl}azet-idine, (2S)-1-(hexyloxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-ylo-xy]propan-2-amine, (2S)-1-(heptyloxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]pr-opan-2-amine, N,N-dimethyl-1-(nonyloxy)-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, N,N-dimethyl-1-[(9Z)-octadec-9-en-1-yloxy]-3-(octyloxy)propan-2-am-ine; (2S)-N,N-dimethyl-1-[(6Z,9Z,12Z)-octadeca-6,9,12-trien-1-yloxy]-3-(o-ctyloxy)propan-2-amine, (2 S)-1-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(pentyloxy)propa-n-2-amine, (2S)-1-(hexyloxy)-3-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-di-methylpropan-2-amine, 1-[(11Z,14Z)-icosa-11,14-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, 1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-N,N-dimethyl-3-(octyloxy)pr-opan-2-amine, (2S)-1-[(13Z,16Z)-docosa-13,16-dien-1-yloxy]-3-(hexyloxy)-N,N-dimethylpro-pan-2-amine, (2S)-1-[(13Z)-docos-13-en-1-yloxy]-3-(hexyloxy)-N,N-dimethylpropan-2-amin-e,1-[(13Z)-docos-13-en-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, 1-[(9Z)-hexadec-9-en-1-yloxy]-N,N-dimethyl-3-(octyloxy)propan-2-amine, (2R)-N,N-dimethyl-H(1-metoyloctyl)oxy]-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-2-amine, (2R)-1-[(3,7-dimethyloctyl)oxy]-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-di-en-1-yloxy]propan-2-amine, N,N-dimethyl-1-(octyloxy)-3-({8-[(1S,2S)-2-{[(1R,2R)-2-pentylcyclopropyl]-methyl}cyclopropyl]octyl}oxy)propan-2-amine, N,N-dimethyl-1-{[8-(2-oclylcyclopropyl)octyl]oxy}-3-(octyloxy)propan-2-am-ine and (11E,20Z,23Z)-N,N-dimethylnonacosa-11,20,2-trien-10-amine, 5-carboxyspermylglycine dioctaoleoylamide ("DOGS"), dipalmitoylphosphatidylethanolamine 5-carboxyspermyl-amide ("DPPES"), 1,2-dimyristyloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide (DMRIE), DMRIE-HP, Lipofectamine (DOSPA), 3b-(N-(N′,N′-dimethylaminoethane)-carbamoyl)cholesterol ("DC-Choi"), N-(1,2-dimyhstyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium bromide ("DMRIE"), 1,2-Dioleoyl-3-dimethylammonium-propane ("DODAP"), DMDMA, cationic lipid-based transfection reagents TransIT-TKO, LIPOFECTIN, Lipofectamine, OLIGOFECTAMINE or DHARMAFECT, DSDMA, DODMA, DLinDMA, DLenDMA, gamma-DLenDMA, DLin-K-DMA, DLin-K-C2-DMA (also known as DLin-C2K-DMA, XTC2, and C2K), DLin-K-C3-DM A, DLin-K-C4-DMA, DLen-C2K-DMA, y-DLen-C2K-DMA, DLin-M-C2-DMA (also known as MC2), DLin-M-C3-DMA (also known as MC3) or (DLin-MP-DMA)(also known as 1-B11), or mixtures thereof. It is not. The above non-cationic lipid is specifically exemplified by US 2018 / 0311176 A, US 2019 / 0032051 A, etc., and may be, for example, phosphatidylglycerol, cardiolipin, diacylphosphatidylserine, diacylphosphatidic acid, N-dodecanoyl phosphatidylethanolamine, N-succinyl phosphatidylethanolamine, N-glutaryl phosphatidylethanolamine, or lysylphosphatidylglycerol.경우에 따라서, 상기 비양이온성 지질은 예를 들어, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, 1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), cholesterol, phosphatidylglycerols, cardiolipins, diacylphosphatidylserines, diacylphosphatidic acids, N-dodecanoyl phosphatidylethanolamines, N-succinyl phosphatidylethanolamines, N-glutarylphosphatidylethanolamines, lysylphosphatidylglycerols, palmitoyloleyolphosphatidylglycerol (POPG)일 수 있으나, 이에 제한되는 것은 아니다. The above neutral lipids are specifically exemplified in US 2018 / 0311176 A, US 2019 / 0032051 A, etc., and may include, but are not limited to, diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, dihydrosphingomyelin, cephalin, or cerebrosides. To prevent aggregation of particles generated during the above mRNA delivery, PEG fat may be included. PEG fat is specifically exemplified in US 2018 / 0311176 A, US 2019 / 0032051 A, etc., and may be, but is not limited to, PEG-diacylglycerol (DAG), PEG-dialkyloxypropyl (DAA), PEG-phospholipid, PEG-ceramide (Cer), or mixtures thereof. In another aspect, the nucleic acid construct according to the present invention can be delivered via nanoparticles, for example, gold nanoparticles. The gold nanoparticles may have a modified surface. Specific examples of modifications are described in Acc Chem Res. 2019 June 18; 52(6): 1496-1506 and Pharmaceutics 2021, 13, 900, which are incorporated herein by reference. The nucleic acid structure can be delivered to cells by linking gold nanoparticles and forming a complex with a cationic endosomal disruptive polymer (Nature Biomedical Engineering volume 1, pages 889-901 (2017)). The cationic endosomal disruptive polymer can be, for example, a block copolymer of polyethylene imine, poly(arginine), poly(lysine), poly(histidine), poly-[2-{(2-aminoethyl)amino}-ethyl-aspartamide] (pAsp(DET)), poly(ethylene glycol) (PEG) and poly(arginine), a block copolymer of PEG and poly(lysine), or a block copolymer of PEG and poly{N-[N-(2-aminoethyl)-2-aminoethyl]aspartamide} (PEG-pAsp(DET)). In some cases, gold particles with arginine-modified surfaces can be used. The arginine-modified gold particles can be assembled with a nuclease or a polynucleotide encoding it and / or a cleavage factor or a polynucleotide encoding it. This allows them to fuse with the membrane of the target cell and translocate into the cytoplasm (ACS Nano. 2017, 11:2452-2458). In another aspect, peptides may be used to deliver nucleic acid structures according to the present invention. The peptide must have a cationic moiety capable of electrostatically interacting with the anionic phosphate groups of the nucleic acid, and may include positively charged amino acids for electrostatic interaction with the phosphate groups. Specific details of peptides usable for mRNA delivery are described in AIMS Biophysics, 7(4): 323-338, which is incorporated herein by reference. The peptides that can be used for delivery of the above nucleic acid structure may include protamine. Protamine is a small, cationic, arginine-rich nuclear protein that contributes to the stability of DNA during spermatogenesis in the testis. Protamine stabilizes mRNA molecules, enabling efficient delivery. A protamine-mRNA complex is specifically described in US 9352028 B, which is incorporated herein by reference. Cell-penetrating peptides (CPPs) may also be promising cationic molecules for delivery of nucleic acid constructs. Non-limiting examples of such cationic molecules include, but are not limited to, amphipathic CPPs such as the arginine-rich RALA peptide (WEARLARALARALARHLARALARALRACEA: SEQ ID NO: 117), LAH4 (KKALLALALHHLAHLALHLALALKKA: SEQ ID NO: 118), and LAH4-L1 (KKALLAHALHLLALLALHLAHALKKA: SEQ ID NO: 119). In addition to the liposomes or LNPs described above, peptides may be additionally included for mRNA delivery, if desired. These peptides can provide nucleic acid packaging and protect DNA or RNA from degradation either intracellularly or extracellularly. Examples of such peptides are specifically described in US 2021 / 0170046 A, which is incorporated herein by reference, but is not limited thereto. The pharmaceutical composition according to the present invention may contain a pharmaceutically effective amount of the nucleic acid structure alone, or may contain one or more pharmaceutically acceptable carriers, excipients, or diluents. The pharmaceutically effective amount herein refers to an amount sufficient to prevent, improve, or treat the target disease. The above “pharmaceutically acceptable” means physiologically acceptable and does not typically cause allergic reactions such as gastrointestinal upset or dizziness or similar reactions when administered to humans. Examples of the carrier, excipient, and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition, the pharmaceutical composition may further include fillers, anticoagulants, lubricants, wetting agents, fragrances, emulsifiers, and preservatives. The term "carrier" is defined as a compound that facilitates the introduction of a nucleic acid structure into cells or tissues. For example, dimethyl sulfoxide (DMSO) is a commonly used carrier that facilitates the introduction of many organic compounds into the cells or tissues of living organisms. The term "diluent" is defined as a compound that stabilizes the biologically active form of the target compound and is diluted in water to dissolve the compound. Salts dissolved in buffer solutions are used as diluents in the field. A commonly used buffer solution is phosphate-buffered saline, as it mimics the salt content of human body fluids. Because buffer salts can control the pH of a solution at low concentrations, buffer diluents rarely alter the biological activity of a compound. A pharmaceutical composition containing a nucleic acid structure according to the present invention may be administered to a patient as such or as a pharmaceutical composition mixed with other active ingredients or with a suitable carrier or excipient, such as in combination therapy. The pharmaceutical composition of the present invention can be administered through various routes including oral, transdermal, subcutaneous, intravenous or intramuscular, and the dosage of the active ingredient can be appropriately selected depending on various factors such as the route of administration, the patient's age, sex, weight and the patient's severity. Pharmaceutical compositions suitable for use in the present invention include those containing a nucleic acid structure encoding an active ingredient in an amount effective to achieve the intended purpose. More specifically, a therapeutically effective amount refers to an amount of a compound effective to prolong the survival of a subject being treated, or to prevent, alleviate, or relieve symptoms of a disease. Determination of a therapeutically effective amount is within the capabilities of those skilled in the art, particularly in light of the detailed disclosure provided herein. In the present invention, “subject” means a mammal suffering from or at risk of a condition or disease that can be alleviated, suppressed or treated by administering a nucleic acid construct according to the present invention, and preferably means a human. The dosage of the nucleic acid structure of the present invention to the human body may vary depending on the patient's age, body weight, sex, dosage form, health condition, and degree of disease. The toxicity and therapeutic efficacy of compositions comprising the nucleic acid constructs described herein can be estimated by standard pharmaceutical procedures in cell cultures or experimental animals, for example, to determine the LD50 (the lethal dose for 50% of a population), the ED50 (the dose that has a therapeutic effect for 50% of a population), and the IC50 (the dose that has a therapeutic inhibitory effect for 50% of a population). The dose ratio between toxic and therapeutic effects is the therapeutic index, which can be expressed as the ratio of the LD50 to the ED50 (or IC50). Compounds exhibiting a high therapeutic index are preferred. Data obtained from these cell culture assays can be used to estimate a range of doses for use in humans. The dosage or application amount of such compounds is preferably within a range of circulating concentrations that include the ED50 (or IC50) with little or no toxicity. The term “administration” of the present invention means an act of introducing the pharmaceutical composition of the present invention into a subject by any appropriate method, and the route of administration may be through various routes, such as oral or parenteral, as long as it can reach the target tissue. The pharmaceutical composition of the present invention may be administered via any conventional route as long as it can reach the target tissue. The pharmaceutical composition of the present invention is not particularly limited thereto, but may be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, orally, intranasally, intrapulmonary, or rectally, depending on the intended use. Furthermore, the composition may be administered via any device capable of transporting the active ingredient to target cells. The pharmaceutical composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents. It can also be administered singly or in multiple doses. Taking all of the above factors into consideration, it is important to administer the amount that achieves maximum efficacy with the minimum amount possible without causing side effects. The pharmaceutical composition according to the present invention may be formulated as an injectable formulation such as an aqueous solution, suspension, emulsion, etc., but is not limited thereto, and is preferably provided in a lyophilized form. For the preparation of a lyophilized formulation, a method commonly known in the art to which the present invention pertains may be used, and a stabilizer for lyophilization may be added. Furthermore, the composition may be preferably formulated according to each disease or ingredient using an appropriate method in the art or a method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA). Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples. Example 1: Establishment of a structure for protecting the poly(A) end of mRNA. In order to protect poly(A) from exonuclease (deadenylase), it was determined that protein binding to the terminal region should be induced or exposure should be prevented as much as possible through structure formation. However, unlike proteins, mRNA is composed of nucleotides, so the structure can be formed through unintended complementary binding, and there is a high probability that the efficacy will be halved as an innate immune response mechanism by TLR3 (Sergio Linares-Fernandez, et al., Trends Mol Med. 2020 Mar;26(3):311-323) (recognizing 35 nt complementary binding sequence) upon intracellular penetration. Therefore, in selecting candidates, we focused on the structural sequences that have already been experimentally applied to the human body. Selection was conducted based on virus-derived sequences (Hiroyasu Wakida, et al., Biochem Biophys Res Commun. 2020 Jul 5;527(4):993-999, Kathrin Leppek, et al., Nat Commun. 2022 Mar 22;13(1):1536). This is because RNA viruses have evolved over a long period of time to have sequences for evading innate immune mechanisms and for efficient protein expression within host human cells, and so we sought to utilize sequence regions where pathogenic effects do not occur. As a result, the Dengue virus (DENV) sequence was selected. It has been reported that DENV has acquired a motif of three complementary binding sites (5'-3' UAR / DAR / CS) that can increase stability through self-evolution (Fig. 1; the three complementary binding sites (5'-3' UAR / DAR / CS) are indicated by red boxes). Due to this structure, DENV is known to exhibit high virus replication and translation efficiency (Nestor G lglesias, Andrea V Gamarnik, RNA Biol. 2011 Mar-Apr;8(2):249-57). By combining the above three structural sequences (5'-3' UAR / DAR / CS), we designed a platform structure that double-strands the single-stranded portion of the unstable adenosine (A) terminal after insertion into the middle and end of poly(A) and shields the mRNA from exonuclease attack, thereby increasing stability and translation efficiency (Fig. 2). This structure is likely to block the access of exonuclease by forming a double-strand or secondary structure through complementary binding to the poly(A) terminal region (Stefan Bresson, David Tollervey, Open Biol. 2018 Mar;8(3):170270) (Fig. 3), and can function independently without interference with the UTR and CDS sequences, so it can be utilized as a universally applicable platform. Example 2: mRNA construct design and secondary structure prediction In the DENV sequence, the UAR / DAR / CS regions are each divided into independent regions. In the present invention, the base sequences of the three regions containing the bulge structure were modified and linked to increase the probability of maintaining complementary binding while evading innate immune mechanisms (Table 1, Fig. 4). After designing the mRNA expression cassette construct, we performed a SHAPE-Map assay that can experimentally predict the structure of the mRNA synthesized in vitro, and confirmed that the complementary sequences of the modified DENV complementarily bind to each other to form a secondary structure (Fig. 5; Red box: formation of secondary structure through complementary binding of CS1 and CS2). Example 3: Protein expression level testing for in vitro proof-of-concept In addition to the construct in Fig. 5, pDNA of constructs (Table 2) was synthesized to confirm the effect of various combinations of poly(A) numbers and secondary structure formation by complementary bonding of CS on increasing protein expression, mRNA was secured through IVT, and transfection was performed into HeLa cells. After transfection, the media was harvested at early time (~7 h) or late time (24 h & 48 h), and the activity of secreted alkaline phosphatase (SEAP) was measured, and the results are shown in Fig. 6. A poly(A) structure at the 3' end consisting of 64 units 64 (Control; #1) A with CS1 / CS2 sequences that can be complementarily combined 32-CS1-A 32 - It was observed that the SEAP activity generated from the mRNA structure (PLA0) in the form of CS2 increased (Fig. 6). In order to confirm whether the above phenomenon was an effect due to the complementary binding of the CS1 and CS2 sequences, an experiment was conducted to compare the SEAP activity by producing a construct in which CS2 was removed and modified. PLA1, which was expected not to form a complementary binding structure due to the absence of the last CS2 sequence, and PLA14, which could not complementarily bind to the CS1 sequence by replacing the CS2 sequence with the reverse sequence of the existing sequence, were produced and the effect was confirmed. As a result, it was confirmed that the protein expression efficiency of PLA1 decreased compared to the protein expression efficiency of PLA0. In addition, in the case of the protein expression efficiency of PLA14, #1(A 64 ) was observed to have a similar protein expression efficiency. As a result, it was confirmed by SHAPE-Map assay that the complementary binding of CS1 and CS2 sequences can form a secondary structure (Fig. 5), and it was demonstrated that this secondary structure can increase the protein expression level of the corresponding mRNA by shielding the Poly A terminus (Fig. 6). Example 4: Search for optimal poly(A) number combinations using complementary binding structures according to the present invention. To find the optimal combination of poly(A) with the best protein expression efficiency, tests were conducted on various combinations of poly(A) in front of CS1 (proximal poly(A)) and poly(A) between CS1 and CS2 (distal poly(A)). Previous reports have shown that total poly(A) sequences and poly(A) binding protein (PABP) that binds to these poly(A) sequences protect the poly(A) termini from the attack of the deadenylase complex, thereby increasing RNA stability and playing an important role in inducing protein translation initiation. Therefore, it seems that the greater the number of poly(A) that PABP can bind, the higher the protein expression efficiency. However, recent reports have shown that there is a minimum number of poly(A) that PABP can bind to (Michael W Webste, et al., Mol Cell. 2018 Jun 21;70(6):1089-1100.e8; Seung Hwan Lee, et al., Nucleic Acids Res. 2014 Feb;42(4):2697-707). Therefore, based on the minimum number required for PABP to bind, the protein expression efficiency according to various combinations of poly(A) numbers was verified (Table 3, Fig. 7). The purpose of this experiment was to find the optimal PABP binding combination that could shield the poly(A) terminal region using CS1 and CS2, thereby inducing stable protein expression. As a result, it was confirmed that protein expression efficiency was increased when the number of proximal poly(A) at the frontmost part of the A-CS1-A-CS2 structure and the number of distal poly(A) existing between CS1 and CS2 were 12 or more (Fig. 8). Example 5: Exploration of additional constructs capable of enhancing protein expression using complementary binding sequences. After searching for various combinations of structures using the CS1 and CS2 sequences as shown in Table 4 and Figure 9, it was confirmed that the CS1 and CS2 structures can be applied to various combinations (Figure 10). {(A) m -CS1-(A) n -CS2-(A) o} p The structures of (chemical formula (I)) It was produced by amplifying the poly(A) region by adding poly(A) to the end of CS2, and A 100 We confirmed that protein expression efficiency was increased compared to the control. These results suggest the technological potential for further optimization to achieve superior efficacy, as protein expression efficiency is increased without functional problems even when an A sequence is present after the CS2 sequence. [(A) m -CS1-{(A) r -(G / C / U)} x -(A) y -CS2] p (chemical formula (III)), [(A) m -CS1-{(A) r -(G / C / U)} x -{(A) s -(G / C / U)} x' -CS2] p (chemical formula (IV)), [{(A) r -(G / C / U)} x -(A) y -CS1-(A) n -CS2] p (chemical formula (V)), [{(A) r -(G / C / U)}x -(A) y -CS1-{(A) r -(G / C / U)} x' -(A) y' -CS2] p (chemical formula (VI)), [{(A) r -(G / C / U)} x -(A) y -CS1-{(A) s -(G / C / U)} x' -CS2] p (chemical formula (VII)), [{(A) r -(G / C / U)} x -(A) y -CS1-{(A) r -(G / C / U)} x' -{(A) s -(G / C / U)} x' -CS2] p The structures of (Formula (VIII)) were constructed by including a combination of sequences, designated Mixed tail or Non-A, which have functionally similar actions to poly(A), either or both, in the proximal poly(A) region and the distal poly(A) region. As a result of the efficacy test, all of them were A 100 We confirmed that the protein expression efficiency tended to be superior to that of the control. These results suggest that even for non-A sequences with similar functions to typical poly(A) sequences, the combination of CS1 and CS2 sequences can further increase protein expression efficiency. {(N) q -(A) m -CS1-(A) n -CS2} p The structures of (chemical formula (II)) were produced by inserting a sequence named ARS (Adenine Rich Site) with a similar function to poly(A) in front of the proximal poly(A) region, and the effect of increasing protein expression efficiency was confirmed, suggesting the technological potential to derive superior efficacy. Example 6: Sequence and structure optimization of CS1 and CS2 To verify the concept of increasing RNA stability and protein expression efficiency by forming complementary binding sequences of CS1 and CS2 in the middle or end of poly(A), some of the sequences derived from DENV virus that are known to have no pathogenic effect were modified and applied and verified. In addition, since the formation of complementary binding structures plays an important role in increasing protein production efficiency, the same effect can be expected even if this is replaced with a sequence that can artificially induce complementary binding structures other than the DENV virus-derived sequence. Therefore, the PLA21 construct was created to confirm this and its effect was verified (Fig. 11). As a result, PLA21 is A 64 It was confirmed that the protein production efficiency increased by more than 2 times compared to the control (#1) (Fig. 11). However, it showed an effect that was about 2 times lower than the PLA0 construct using the complementary binding sequence derived from the DENV virus. It was expected that this difference would be due to the structural characteristics that specifically appear in the complementary sequence derived from the DENV virus. In order to confirm this, the structures of the PLA0 and PLA21 constructs were compared using RNAfold (http: / rna.tbi.univie.ac.at / cgi-bin / RNAWebSuite / RNAfold.cgi), a tool for predicting secondary structure formation, and as a result, it was confirmed that the bulge part specifically formed between the complementary binding structure between CS1 and CS2 was different in PLA0 and PLA21 (Fig. 11). Recently, it has been reported that double-strand structures of viral RNA longer than a certain length (>33 nt) can induce an innate immune response, but this can vary depending on the presence or absence of a bulge within the double-strand structure. In particular, it is well known that this innate immune response inhibits the stability of the corresponding RNA and protein translation efficiency within the cell. Therefore, it was judged that the formation and structural form of the bulge part would play an important role in regulating protein expression efficiency. To confirm this and find the optimal complementary binding sequence of CS1 and CS2, constructs with various lengths and sequence combinations of bulge formation and complementary binding sequences were produced and tested (Table 5 and Figure 12). As a result, it was confirmed that the complementary sequence was present at 30% to 100%, and that the protein expression efficiency was significantly increased when the bulge structure was present in the DENV-derived complementary sequence (Fig. 13). Example 7: Verification of protein expression efficiency of nucleic acid constructs in which the GOI of candidates with increased protein expression efficiency was changed to Gaussia luciferase. The GOI (Gene of Interest) used in the candidate search of Examples 4 to 6 utilized the SEAP gene sequence. To determine whether the effect of secondary structure formation through complementary binding of CS on increasing protein expression efficiency was also observed in other GOIs, experiments were conducted by replacing the gene sequence encoding SEAP with the Gaussia luciferase gene sequence. The tests used candidates that were ranked high in the results of Examples 4 and 6 (Fig. 14). As a result, it was confirmed that the application of the structures of chemical formulas (I) to (VIII) induced significantly increased protein expression in GOIs other than SEAP (Fig. 15). Example 8: Verification of protein expression efficiency of nucleic acid constructs containing various UTRs. The 5'-UTR applied to the screening test of Examples 4 to 6 was RPL32, and the 3'-UTR was HBA1. In order to confirm whether the secondary structure formation by complementary binding of CS also has the effect of increasing protein expression efficiency in other UTRs, the protein expression efficiency was compared after applying 20 different UTRs (Table 6, Fig. 16). As a result, when CS1 and CS2, such as the structure according to the present invention, are applied to all UTRs, the protein expression efficiency is A 90 A trend of more than two times increase compared to the control was confirmed (Fig. 17). Example 9: Verification of the stability of the poly(A) region during pDNA amplification in the final selected structures. Most therapeutic mRNA synthesis processes involve in vitro transcription (IVT) using linearized pDNA containing an uninterrupted AT base pair region encoding a poly(A) tail as a template. pDNA is obtained from Escherichia coli (E. coli) cultures lacking recombinase. However, even in E. coli lacking recombinase, homopolymer regions, in which identical sequences are repeated for a certain length, such as the poly(A) tail region, are highly unstable and are often cleaved during replication and cell division in E. coli cultures. This phenomenon increases proportionally as the length of the homopolymer region increases. It is expected that the fractionation of the homopolymer region within the template pDNA due to the introduction of CS1 will relatively shorten the length of the continuous A sequence, ultimately improving the stability of the poly(A) region during pDNA replication in E. coli. To confirm this, stability tests for the poly(A) region during pDNA replication were performed in three different strains of E. coli (DH10B, TOP10, and NEB®Stable). As a result, continuous A 79 or A 100 It was confirmed that the pDNA with CS1 and CS2 had a reduced stability in maintaining the poly(A) region due to the cleavage of a portion of the A sequence in the poly(A) tail portion. On the other hand, this phenomenon was reduced in the construct with CS1 and CS2 inserted, confirming that the stability of the poly(A) region in the pDNA was improved (Fig. 18). Example 10: Inhibition of double-stranded RNA (dsRNA) production during in vitro transcription (IVT) During in vitro transcription (IVT), double-stranded RNA (dsRNA) is produced as a byproduct of the reaction. This generated dsRNA exhibits immunogenic properties, acting as an agonist for toll-like receptor 3 (TLR3) and melanoma differentiation-associated protein 5 (MDA5) upon entry into cells, inducing cytokine release. This immunogenicity of dsRNA induces cytotoxicity. Furthermore, the body recognizes RNA introduced by immunogenicity as viral RNA and attempts to degrade it, thereby reducing RNA translation efficiency. Therefore, controlling immunogenicity, particularly reducing the production of dsRNA, is essential for enhancing the efficacy of vaccines or gene therapy agents. In this example, an experiment was conducted to confirm whether the region in which the CS1 and CS2 were inserted was recognized as double-stranded RNA because the structure was complementarily combined. The amount of dsRNA was confirmed by an enzyme-linked immunosorbent assay (ELISA) using an anti-dsRNA J2 antibody, and the GOI of the candidate group present in the upper rank in the results of Examples 4 and 6 was used by changing the FLuc gene sequence (Fig. 19). As a result, when IVT was performed using the same method, the complementary binding formed by CS1 and CS2 was not only not recognized as dsRNA by the anti-dsRNA J2 antibody, but it was also confirmed that the amount of double-stranded RNA produced after the IVT reaction was significantly reduced compared to the control when CS was applied (Fig. 19). Example 11: Immunogenicity verification of the final selected construct RNA induces inflammation through multiple pathways, particularly through the innate immune system, which has numerous RNA-detecting sensors. RNA-mediated innate immune responses can result in decreased intracellular RNA translation, systemic / local toxicity, and inflammatory responses, which can impact the expected efficacy and safety of pharmaceuticals. To evaluate the degree of induction of innate immune response by the construct according to the present invention, the cytokine expression pattern according to RNA introduction into monocytes and macrophages was analyzed. In Example 10, mRNA containing the final poly(A) tail structure was delivered to THP-1 cells, a human cell line derived from acute myeloid leukemia, and macrophages derived from THP-1 cells differentiated with PMA (phorbol 12-myristate 13-acetate) using MessengerMAX™. 6 and 24 hours after transfection, the concentrations of Type I interferon, inflammatory cytokines, and chemokines secreted as a result of the innate immune response in the culture medium were measured. Compared to the introduction of the mRNA construct (PLA321) having a continuous A79 in the form of a poly(A) tail into monocytes, significantly lower levels of type I interferon (IFN-α, IFN-β) and inflammatory cytokines (IL-1β), and chemokines (MCP-1, MIP-1β, IP-10) were detected in the cell culture medium when the mRNA construct (PLA322-325) according to the present invention was introduced into monocytes (Fig. 20). Similarly, when the mRNA construct (PLA322-325) according to the present invention was introduced into THP-1-derived macrophages differentiated with PMA, A 79Compared to the case where the mRNA construct (PLA321) with a Poly(A) tail was introduced, significantly lower levels of Type I interferon (IFN-α) and inflammatory cytokines (IL-1β, IL-6), and chemokines (MCP-1, MIP-1β, IP-10) were detected in the cell culture (Fig. 20). This suggests that the application of the nucleic acid structure according to the present invention has the potential to induce a low level of innate immune response, and is a suitable characteristic for application to a pharmaceutical composition for vaccines or gene therapy. The nucleic acid structure platform according to the present invention exhibits enhanced stability and protein expression rates within cells without interference with CDS, UTR sequences, etc., making it suitable for general use in fields such as gene therapy and vaccines. Furthermore, it can be used to protect against Poly A cleavage, a concern during mRNA preparation production, from the pDNA state, thereby enabling the production of intact mRNA preparations. While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents. Electronic file attached.

Claims

1. A nucleic acid structure comprising a coding region (CDS) encoding a polypeptide or protein; and a poly(A) tail having a structure of any one of the following chemical formulae (I) to (VIII): In the above chemical formulas (I) to (VIII), The above G / C / U means G (guanine), C (cytosine) or U (uracil), The above N represents U (uracil), G (guanine), A (adenine), or C (cytosine), The above m is an integer from 5 to 200, the above n is an integer from 3 to 200, the above o is an integer from 3 to 200, the above p is an integer from 1 to 10, the above q is an integer from 0 to 200, the above r and s are integers from 1 to 30, the above x and x' are integers from 1 to 10, the above y and y' are integers from 0 to 80, The above CS1 and CS2 are characterized in that they bind complementarily to each other.

2. A nucleic acid structure characterized in that in the first paragraph, the poly A tail has a structure of the chemical formula (I), wherein m is an integer from 10 to 100, n is an integer from 10 to 50, o is an integer from 10 to 30, and p is an integer from 1 to 5.

3. A nucleic acid structure characterized in that in paragraph 1, CS1 and CS2 are complementarily combined to form a stem-loop structure, a bulged stem structure, or a pseudoknot structure, or are complementarily combined by 30% to 100%.

4. A nucleic acid structure according to claim 3, wherein CS1 is represented by any one of the base sequences of SEQ ID NO: 1 to SEQ ID NO:

9.

5. A nucleic acid structure according to claim 3, wherein CS2 is represented by any one of the base sequences of SEQ ID NO: 10 to SEQ ID NO:

18.

6. A nucleic acid structure according to claim 1, wherein the poly A tail is represented by any one of the base sequences of SEQ ID NO: 24 and SEQ ID NO: 29 to SEQ ID NO:

102.

7. A nucleic acid structure according to claim 1, characterized in that it comprises a modified nucleic acid.

8. A nucleic acid structure according to claim 7, characterized in that the modified nucleic acid is selected from the group consisting of pseudouridine (Ψ), N1-methyl-pseudouridine (m1Ψ), 5-methyl-uridine (m5U), 2-thio-uridine (s2U), 2'-O-methyl-uridine (2'-O-methyl-U, Um), 5-methyl-cytidine (m5C), and 5-methoxy-uridine (5-methoxyuridine, 5moU).

9. A nucleic acid structure characterized in that it further comprises a 5'-untranslated region (5'-UTR) and a 3'-untranslated region (3'-UTR) connected to both ends of the coding region in the first paragraph; and a 5'-cap or IRES connected to the 5'-untranslated region.

10. In the first paragraph, the polypeptide or protein (a) a therapeutically active protein or peptide; or (b) an antigen selected from the group consisting of tumor antigens, pathogenic antigens, viral antigens, protozoal antigens, bacterial antigens, allergic antigens and autoimmune antigens; A nucleic acid structure characterized by:

11. A vaccine comprising a nucleic acid structure according to any one of claims 1 to 10.

12. A pharmaceutical composition for gene therapy comprising a nucleic acid structure according to any one of claims 1 to 10.

Citation Information

Patent Citations

  • Artificial nucleic acid molecules comprising a 5'top utr

    EP2831240A2

  • Stabilization of poly(a) sequence encoding DNA sequences

    US20170166905A1

  • Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein

    US20180185517A1

  • Nanoparticle formulations for delivery of nucleic acid complexes

    US20180311176A1

  • Non-liposomal systems for nucleic acid delivery

    US20190032051A1

Cited By

  • Novel nucleic acid construct comprising poly(a) tail having secondary or tertiary structure and containing non-a sequence at terminus, and uses thereof

    WO2026089123A1